Q901 — Investigational Agent
Other · Phase 1/2 · Qurient
Mechanism of Action
Highly selective covalent inhibitor of cyclin-dependent kinase 7 (CDK7). CDK7 governs both cell-cycle progression (as CAK) and transcription via RNA Pol II CTD phosphorylation; inhibition downregulates oncogenic super-enhancer-driven transcription (e.g., MYC, cyclins) and is preferentially cytotoxic in transcriptionally addicted tumors.
Investigational Indications
- Ovarian cancer
- Pancreatic cancer
- HR+/HER2- breast cancer
- Small cell lung cancer